MLC901 in Hypoxic-ischemic Brain Injury Patients; A Double-blind, Randomized Placebo-controlled Trial
Status:
Completed
Trial end date:
2022-08-12
Target enrollment:
Participant gender:
Summary
In a randomized, placebo-controlled trial, 35 patients with HIBI were randomly designated to
receive either MLC901 or placebo capsules over six months.
We evaluated patients in two groups by modified Rankin Scale (mRS) and Glasgow outcome scale
(GOS) to examine their state of disability and recovery